New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 28, 2024 - The FDA approved Tanvex’s Nypozi (filgrastim-txid), biosimilar to Amgen’s Neupogen (filgrastim).
Download PDF
Return to publications
